Announcements Trials
Browse Landscape

Phase

Phase 2/3 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 24Lymphoid 16Other hematologic neoplasm 12Thoracic 2Tumor-Agnostic 1Head & Neck 1Gynecologic 1Gastrointestinal 1CNS 1

Conditions

Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2

Interventions

Carboplatin 106pembrolizumab 93Pemetrexed 80Cisplatin 68Specimen Handling 44Paclitaxel 38durvalumab 36Nivolumab 36Docetaxel 33Magnetic Resonance Spectroscopy 32osimertinib 28atezolizumab 26Etoposide 22Gemcitabine 21Radiotherapy 19130-nm albumin-bound paclitaxel 18Cetuximab 16amivantamab 14Radiosurgery 14Radiation 12Platinum 12Ipilimumab 12Bevacizumab 12lazertinib 11cemiplimab 11Taxes 11Immunoglobulin G 11Topotecan 10Ramucirumab 10Disulfides 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Calcium Dobesilate × Thoracic × 30 days × Clear all
NCT05096663 2026-05-18

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

SWOG Cancer Research Network

Phase 2/3 Active not recruiting
82 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06616584 2026-05-05

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

SWOG Cancer Research Network

Phase 2/3 Recruiting
378 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡